Home › Compound Library › MOTS-c
Mitochondrial and cellular energy
MOTS-c: The Mitochondrial Peptide That Acts Like an Exercise Signal
The short answer
MOTS-c is a 16-amino-acid peptide encoded in the DNA of your mitochondria, not the cell nucleus. It activates AMPK, the cell’s energy sensor, which improves how cells use glucose and fat, the same switch exercise flips. Mouse studies are strong; human evidence is early, and it is not FDA approved.
Questions people ask about MOTS-c
MOTS-c at a glance
| Stands for | Mitochondrial Open reading frame of the Twelve S rRNA-c |
|---|---|
| What it is | Mitochondrial-derived peptide (16 amino acids) |
| Main system | Mitochondria, insulin sensitivity, metabolic flexibility |
| Evidence level | Investigational: strong animal data, early human data |
| FDA status (Sept 2026) | Not approved. FDA advisory panel voted in July 2026 to recommend it for pharmacy compounding; not yet final |
| Anti-doping | Listed by WADA as a prohibited AMPK activator |
What is MOTS-c?
Almost every peptide in the body is coded in the DNA of the cell nucleus. MOTS-c is one of a small group coded in the mitochondria’s own DNA, inside the gene for 12S ribosomal RNA (Metabolic Precision, pp. 133–134). It was described in 2015 in Cell Metabolism (reference 1).
Levels fall with age and in metabolic dysfunction, which is why it is studied as a kind of mitochondrial hormone the body gradually loses.
How does MOTS-c work?
Its main lever is AMPK, the cell’s master energy sensor. When energy is low, as during exercise or fasting, AMPK switches the cell from storing energy to burning and repairing. MOTS-c activates that switch (Metabolic Precision, p. 134):
- Moves glucose transporters (GLUT4) to the cell surface, so more sugar is taken up
- Increases fat burning
- Encourages new mitochondria through PGC-1α
- Under stress, travels to the nucleus and changes gene expression tied to metabolic adaptation
Because that is so much of what exercise does at the molecular level, MOTS-c is often called an “exercise mimetic.” As The Longevity Map puts it, it nudges the same pathways as disciplined diet and training, “though no peptide substitutes for actually doing those things” (p. 63).
MOTS-c for weight loss and insulin resistance: what the research shows
Animal studies. In the original 2015 study, MOTS-c prevented diet-induced obesity and insulin resistance in mice (reference 1). A 2019 study found it regulates plasma metabolites and improves insulin sensitivity (reference 2). Reviews link it to age-related metabolic decline (reference 3).
Human studies. The best human data so far come from CB4211, a modified version of MOTS-c. In a small 4-week Phase 1b study of 20 people with obesity and fatty liver, it was well tolerated and lowered liver enzymes and blood glucose, with a trend toward lower body weight (reference 4). That is encouraging but small and short, and it tested an analog, not MOTS-c itself.
Bottom line: strong mechanism, good animal evidence, early and limited human evidence.
MOTS-c side effects and safety
- Early research suggests it is generally well tolerated.
- Higher exposure may cause short-term fatigue or energy swings, attributed to overstimulating the energy-sensing pathway (Metabolic Precision, p. 136; The Longevity Map, p. 64).
- Long-term human safety data don’t exist yet.
- Products sold as research chemicals are unregulated.
People asking about combining MOTS-c with GLP-1 drugs such as retatrutide should know there are no interaction studies. That is a conversation for a prescribing clinician.
Is MOTS-c legal or FDA approved?
Not FDA approved. In July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the 503A bulks list, one of six peptides it recommended (references 5, 6). The vote is non-binding and still needs formal sign-off.
For athletes: the WADA Prohibited List names MOTS-c among banned AMPK activators (reference 7).
MOTS-c vs NAD+ vs SS-31
All three are discussed as mitochondrial support, but they work at different points. MOTS-c is a signal: it activates AMPK and changes how cells use fuel. NAD+ is a cofactor, a molecule mitochondria need to run energy reactions at all. SS-31 (elamipretide) is structural: it binds cardiolipin in the inner mitochondrial membrane to protect the energy machinery (Metabolic Precision, pp. 136–137).
Different mechanisms are why they are sometimes studied together, and why the books frame MOTS-c as the most upstream mitochondrial signalling intervention.
MOTS-c: frequently asked questions
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It activates AMPK, the cell’s energy sensor, and is studied for insulin sensitivity, metabolism and ageing.
What does MOTS-c do?
It activates AMPK, which increases glucose uptake and fat burning and encourages new mitochondria. The effect resembles some of the molecular effects of exercise.
Does MOTS-c help with weight loss?
In mice it prevented diet-induced obesity. In humans, a small 4-week study of a modified version showed lower liver enzymes and glucose and a trend toward lower weight. Human proof is still early.
Is MOTS-c FDA approved?
No. An FDA advisory committee voted in July 2026 to recommend it for pharmacy compounding, but that is non-binding and is not a drug approval.
Is MOTS-c a GLP-1?
No. GLP-1 drugs act on the GLP-1 hormone receptor. MOTS-c is a mitochondrial peptide that works through AMPK, a completely different pathway.
Is MOTS-c banned by WADA?
Yes. The WADA Prohibited List names MOTS-c among prohibited AMPK activators.
Does MOTS-c give you energy or make you tired?
It is studied for improving how cells produce and use energy, but higher exposure has been linked to short-term fatigue or energy swings.
Is MOTS-c safe?
Early research suggests good tolerability, but there is no long-term human safety data, and research-chemical products are unregulated.
MOTS-c vs NAD+: what is the difference?
MOTS-c is a signalling peptide that activates AMPK. NAD+ is a cofactor mitochondria need to run energy reactions. They support mitochondria at different points.
Can MOTS-c be taken with retatrutide or tirzepatide?
There are no studies on combining them. The pathways are different, but any combination with a prescription drug should be discussed with the prescribing clinician.
Where MOTS-c appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how MOTS-c fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Related compounds
See how MOTS-c fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. View sourceCited in Targeted Peptide Systems (p. 348), The Cognitive Advantage (p. 408), Metabolic Precision (p. 355), Regenerative Resilience (p. 352) and The Longevity Map (p. 197)
- Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. View sourceCited in Metabolic Precision (p. 355)
- Mohtashami Z, Singh MK, Salimiaghdam N, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. View sourceCited in Metabolic Precision (p. 355)
- CohBar, Inc. Positive topline results from the Phase 1a/1b study of CB4211 (a MOTS-c analog) for NASH and obesity. 2021. Trial NCT03998514. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. MOTS-c is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.